SNY · Sanofi · Metrics
Market Cap
$97.31B
Shares
2.40B
Volume · Oct 16
4.63M
Avg daily vol (3M)
3.01M
SNY metrics
76 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$40.61
Market cap
$97.31B
Price action
20 metricsPrice change (1W)
+1.3%
Price change (30D)
-4.4%
Price change (3M)
-9.1%
Price change (6M)
-15.5%
Price change (YTD)
-16.2%
Price change (1Y)
-18.8%
Trailing year
Price change (5Y)
-16.9%
52-week high
$52.34
52-week low
$39.12
Change from 52-week high
-22.4%
Change from 52-week low
+3.8%
Annualized volatility
23.2%
Annualized volatility (3M)
20.2%
Beta
0.3
RSI (14D)
45.6
Price vs SMA 50
-4.8%
Price vs SMA 200
-9.0%
Avg volume (3M)
3.01M
Relative volume
1.5
Average dollar volume
$128.13M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
2.40B
Valuation
12 metricsP / E (TTM)
21.1
Trailing earnings · reciprocal yield 4.7%
PEG ratio
—
EV / revenue
2.1×
reciprocal yield 46.6%
EV / EBITDA
—
EV / EBIT
17.1×
reciprocal yield 5.8%
P / sales
1.8×
reciprocal yield 55.0%
P / book
1.2
reciprocal yield 81.2%
FCF yield
—
TTM · current market cap
Buyback yield
2.4%
P / FCF
—
P / operating cash flow
7.0
reciprocal yield 14.2%
Earnings yield
4.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
6.0%
Trailing 12 months
Payout ratio
124.4%
Shareholder yield
8.3%
Dividend / share (TTM)
$2.42
Dividend growth YoY
+9.5%
Dividend growth streak
2
Last ex-dividend
2026-05-04
Earnings calendar
2 metricsNext earnings
2026-10-30
Last earnings
2026-07-30
Profitability
9 metricsGross margin
77.6%
Operating margin
12.5%
Trailing 12 months
Net margin
8.6%
Gross profit (TTM)
$35.60B
Operating profit (TTM)
$5.75B
Net income (TTM)
$4.62B
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
22.1%
Growth
11 metricsRevenue growth YoY
+6.2%
Year over year
Net income growth YoY
+40.5%
Revenue (TTM)
$53.48B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-2.4%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
5.7%
Return on assets
3.1%
Debt / equity
0.3
Current ratio
1.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
8.6
Net debt / EBITDA
—
Return on invested capital
5.3%
Trailing 12 months
Net cash
−$17.49B
Latest balance sheet
Cash & equivalents
$7.25B
Total assets
$147.35B
Total debt
$24.74B
Cash flow & spend
7 metricsOperating cash flow (TTM)
$13.81B
Capital expenditures (TTM)
—
R&D (TTM)
$9.45B
SG&A (TTM)
−$11.47B
Stock compensation (TTM)
$380.28M
R&D / revenue
17.7%
Stock compensation / revenue
0.7%
Ownership (13F)
3 metrics13F filers
724
13F filer change QoQ
-29
Institutional ownership
8.1%
Short interest
3 metricsShort interest
0.4%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
50 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1121404
CUSIP
80105N105
13F (30d)
79 filings
76 filers
Visit website
Investor relations